Business Wire

MAVENIR

21.2.2024 13:01:26 CET | Business Wire | Press release

Share
Slovak Telekom Chooses Mavenir’s Converged Packet Core in Core Supply Partnership

Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces that Slovak Telekom has chosen Mavenir’s fully containerised Converged Packet Core solution for deployment in its network – making Mavenir now its selected complete network core technology partner.

Mavenir is already delivering voice and messaging services for the Slovakian operator and will now be providing data services across the packet core domain for “all Gs”, deploying into Slovak Telekom’s private Container-as-a-Service (CaaS) cloud platform. The new agreement will also see Mavenir integrate next-generation capabilities for cloud-native 5G standalone (SA).

This increased delivery to Deutsche Telekom’s subsidiary in Slovakia adds to Mavenir’s previously announced Converged Packet Core solution roll-out for subsidiaries in the Czech Republic (T-Mobile Czech Republic) and in Hungary (Magyar Telekom). This simultaneous, multi-country replacement of existing vendor technologies expands Mavenir’s end-to-end technology supplier footprint across Europe and strengthens a successful long-term partnership with Deutsche Telekom in Germany.

Mavenir’s Converged Packet Core accelerates the move to 5G and speeds the introduction of new enterprise applications and services that harness pivotal 5G capabilities, including low latency and network slicing. The cloud-native architecture – where applications and services are purpose-built for the cloud model – offers easy scaling, hardware decoupling, agility, portability, and resilience across public, private, and hybrid clouds.

Commenting on the new deployment, Slovak Telekom’s CTIO and interim CEO Vladan Peković said: “Mavenir is a proven and trusted technology partner for Slovak Telekom, and its technical competence, cloud-native capabilities and interoperable approach deliver the optimal launchpad for our continuous innovation journey. We are excited to move forward with Mavenir’s Converged Packet Core as the cornerstone of our future services roadmap.”

Ashok Khuntia, President of Core Networks for Mavenir added: “We are delighted to be extending our co-operation with Slovak Telekom, in an agreement that is built on the strong foundations of our long-term partnership. By integrating Mavenir’s Converged Packet Core into its existing network, Slovak Telekom is creating an agile, scalable and robust foundation for the delivery of transformative, differentiated services for its enterprise customers.”

In a unique approach, Mavenir technology unites the macro core with the enterprise core – spanning scenarios from central deployment with additional remote locations to 5G core solutions implemented on-site. By integrating field-upgradeable enterprise network technology into enterprise premises with local data breakout, Mavenir’s remote UPF (User Plane Function) fast-tracks time-to-go-live for campus solutions – with user data transmitted directly to the UPF and available to application servers for reduced latency and increased security for sensitive data.

Notes to editors:

About Mavenir

Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com

Meet Mavenir at Mobile World Congress 2024 (Barcelona, Feb 26 – 29 2024)

To explore our latest innovations, MWC show announcements and learn more about how Mavenir is delivering the Future of Networks – Today, visit our team in Hall 2 (Stand 2H60).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240221638570/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release

Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co

Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release

Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents

Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release

Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and

LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release

The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o

Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release

Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye